Janet Freeman-Daily will lead a discussion and Q&A, following panel presentations by Dr. Bellinda King-Kallimanis (LUNGevity), Anne Loeser (PCDI, Patient Centered Dosing Initiative), Janice Cowden (PCDI), and Lee Jones (Patient/Survivor). Presenters are Mentors for the 2023 IASLC STARS (Supportive Training for Advocates on Research and Science) program.

Audio translations available in Chinese, French, German, Greek, Japanese and Spanish.

Patients, lung cancer research advocates and advocacy organizations.

Upon completion of this activity, the participants should be able to:

• Discover how drug makers have traditionally determined the dose for cancer drugs during early clinical trials
• Find out how the FDA is planning to optimize the calculation of the dose for cancer drugs in the era of targeted therapies
• Hear about the potential impact that patient experience data could have in optimizing the dose
• Learn about the role patient research advocates can play in these discussions

Moderator:

• Janet Freeman-Daily, Lung Cancer Patient and Research Advocate, Co-Founder and President, The ROS1ders, WA, USA

Presenters:

• Janice Cowden, Patient Centered Dosing Initiatives (PCDI), New York, NY, USA
• Lee Jones, Lung Cancer Patient/Survivor, USA
• Bellinda King-Kallimanis, PhD, Director of Patient-Focused Research, LUNGevity Foundation, FL, USA
• Anne Loeser, Patient Centered Dosing Initiatives (PCDI), New York, NY, USA

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

If you need any assistance with this activity, please email: education@iaslc.org.